Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05615-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Jun Ho Yi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Hydrazines, Triazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
The outcomes of patients with myeloma after exposed to penta-classes are extremely poor. Selinexor is the first approved exportin inhibitor for those patients, but intractable toxicities may limit its use. This retrospective study evaluated the real-world efficacy and safety of selinexor plus dexamethasone (XD) and involved 48 patients with multiple myeloma, who were treated from November 2020 to October 2022. Their median age was 64 years, and the median number of prior lines of therapy was 6. The overall response rate was 25%, and the median progression-free survival (PFS) was 2.1 months (95% confidence interval (CI), 1.7-2.5). Patients on a reduced initial dose, delayed treatment, and dose reduction had better PFS. After XD treatment failure, 17 patients received subsequent therapy and had a median PFS of 2.4 months. The median overall survival was 4.6 months (95% CI, 2.3-6.9). Among the patients, 12 (25%) and 17 (35%) experienced dose reduction and delayed treatment, respectively. Our data show that the real-world efficacy of XD treatment in heavily pretreated patients was modest and that improving treatment adherence through reducing initial doses or delaying treatments may improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea.
- Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.
- Department of Internal Medicine, National Cancer Center, Goyang, Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
- Department of Hematology, Gachon University College of Medicine, Incheon, Korea.
- Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Hwasun-gun, Jeollanam-do, Korea.
Zitieren
APA
Yi, J. H., Park, S. S., Min, C. K., Eom, H. S., Byun, J. M., Koh, Y., Yoon, S. S., Lee, J. H., Jung, S. H., Lee, J. J., Yoon, S. E., Woo, S. Y., & Kim, K. (2024). Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis. Annals of Hematology. https://doi.org/10.1007/s00277-024-05615-0
Vancouver
Yi JH, Park SS, Min CK, Eom HS, Byun JM, Koh Y, et al. Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis. Annals of Hematology. 2024. doi:10.1007/s00277-024-05615-0
BibTeX
@article{Yi2024,
author = {Yi, Jun Ho and Park, Sung-Soo and Min, Chang-Ki and Eom, Hyeon-Seok and Byun, Ja Min and Koh, Youngil and Yoon, Sung-Soo and Lee, Jae Hoon and Jung, Sung-Hoon and Lee, Je-Jung and Yoon, Sang Eun and Woo, Sook-Young and Kim, Kihyun},
title = {Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05615-0}
}
EUVIMED